Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Inflammatory bowel disease drug market will reach $9.6bn in 2017, says Visiongain.Visiongain predicts the IBD treatment market will grow in revenues because of the increased use of biological therapies (biologics), such as monoclonal antibodies (mAbs). They dominate the market for revenue generation.
By: Visiongain Visiongain predicts the IBD treatment market will grow in revenues because of the increased use of biological therapies (biologics), such as monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions, they dominate the market for revenue generation. The strength of this market is also reflected in the 30 new treatments undergoing clinical development to treat IBD. Hamza Baig, a pharmaceutical industry analyst in visiongain, said: “The global inflammatory bowel disease market will show robust growth over the next five years. In particular, my expectation is that biologics will drive growth. However, aminosalicylates, the traditional treatment for IBD, will remain an important option for patients, particularly for those residing in emerging markets. This is because a large number of people in these countries do not necessarily have the means to pay for the most expensive biologic therapies. The cost advantage of aminosalicylates will be more pronounced in these countries. “Our report also finds that developed world markets make up the majority of the global IBD market, but that emerging markets will also show strong growth over the next few years. While inflammatory bowel disease is considered a disease of the developed world, as poorer nations industrialise and urbanise we expect the incidence of these conditions to increase. Among developing nations, Russia and India will show the greatest and second greatest growth rates respectively. I also note the global IBD market is dominated by four main players, who I expect will consolidate their positions over the next 10 years.” Visiongain’ · Aminosalicylates · Antibiotics · Corticosteroids · Biologic therapies (biological drugs) · Immunomodulators. That report also predicts the revenues of the 14 leading inflammatory bowel disease treatments to 2023, including Remicade, Humira and Asacol. The study analyses the R&D pipeline for IBD treatments too, and shows research interviews. It also shows overall IBD revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC). Inflammatory Bowel Diseases: World Drug Market 2013-2023 adds to Visiongain’ For sample pages and further information concerning the Visiongain report Inflammatory Bowel Diseases: World Drug Market 2013-2023 please visit http://www.visiongain.com/ For an executive summary please contact: Sara Peerun sara.peerun@ Tel: +44 (0) 20 7336 6100 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@ About visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. End
Account Phone Number Disclaimer Report Abuse
|
|